Tag Archives: C difficile and Infection Prevention

Global C. difficile Awareness Campaign Begins November 1st – Are You Ready?

As many people in the healthcare and infectious disease industry are aware,
Clostridium difficile (C. difficile) infections remain a significant problem
in the United States. The U.S. Centers for Disease Control and Prevention (CDC) reports that about 250,000 C. difficile infections occur per year that require hospital treatment or affect those already hospitalized. On top of that, each year an estimated 14,000 people die
from C. difficile infection.

The severity of this problem is one reason why I am proud to join the C Diff Foundation’s Medical Advisory Board. The C Diff Foundation is dedicated in educating and advocating for C. difficile infection prevention, treatments, environmental safety products, and support worldwide while providing support for those affected by a
C. difficile infection , raiseis awareness about the problem and works to help healthcare
providers, facilities, patients and their families implement preventative measures worldwide.

Please join me and the C Diff Foundation in celebrating the 4th annual worldwide month long campaign  “Raising C. difficile Awareness ” starting Nov. 1st to increase awareness of this life-threatening infection, and spread the word about C. difficile prevention, treatment and environmental safety.

C. difficile infections are preventable, so healthcare facilities need to focus on the following strategies (adapted from the Centers for Disease Control and Prevention) to help protect their patients, staff and visitors from infection:

C. difficile Prevention Tips:

  1. Antibiotic Stewardship – Prescribe and use antibiotics carefully. Unnecessary use can raise infection risks.
  2. Test – If a patient has diarrhea while on antibiotics or after taking them, order a C. difficile test right away to confirm whether he/she is infected.
  3. Isolation Precautions – Immediately isolate patients with confirmed
    cases of C. difficile or who are exhibiting symptoms (e.g., diarrhea).
  4. Personal Protective Equipment – Always perform hand hygiene with soap and water before and after contact with infected individuals. Wear gloves and gowns when treating C. difficile patients and ensure that staff uses them properly to avoid cross-contamination risks.
  5. Environmental Decontamination – Clean the facility, especially rooms of patients with      C.  difficile, with bleach or another EPA-registered spore-killing disinfectant. Make sure you follow manufacturers’ instructions for dilution and contact time, the length of time the surface needs to remain wet for the product to work. Also consider supplementing standard terminal cleaning with an ultraviolet (UV-C) system.
  6. Alert – If a patient with C. difficile transfers, notify the new facility of their condition so they can take the proper precautionary measures.

To download a free infographic poster on preventing C. difficile facility wide, visit: http://www.cloroxprofessional.com/industry/health/knowledge-expertise/cdiffinfographic/

I

C. difficile Infection (CDI) Prevention, Treatment, Environmental Safety, Research, Clinical Trials Being Discussed with World Topic Experts On September 20th In Atlanta, Georgia USA

Cdiff2015BallroomPic

September 20th

It is with great pride and certainty in the power of the healthcare community to present the 4th Annual International Raising. C. diff. Awareness Conference and Health Expo

being hosted at the

DoubleTree by Hilton — Atlanta Airport 
3400 Norman Berry Drive
Atlanta,Georgia 30344 USA  (Hotel Phone: 1-404-763-1600)

Doors open at 7:15 a.m — Sign In and Continental Breakfast

Conference begins at: 7:30 a.m. – 5:00 p.m.

TAtlantaPic

Raising C. difficile awareness is essential to build upon and advance existing knowledge and necessary for overcoming the challenges our healthcare communities are faced with today.

“None of us can do this alone — All of us can do this together”

Nearly half a million Americans suffered from Clostridium difficile (C. diff.) infections in a single year according to a study released February 25, 2015 by the Centers for Disease Control and Prevention (CDC).   C. diff. is a leading cause of infectious disease death worldwide; 29,000 died within 30 days of the initial diagnosis in the USA.   Previous studies indicate that C. diff. has become the most common microbial cause of healthcare-associated infections found in U.S. hospitals driving up costs to $4.8 billion each year in excess health care costs in acute care facilities alone.

###

Cdiff2015-1Clinical professionals gather for one day to present up-to-date data to expand on the existing knowledge and raise awareness of the urgency focused on a Clostridium difficile infection (CDI) —

    • Prevention
    • Treatments
    • Research
    • Environmental Safety
    • Clinical trials and studies

WITH

  • Microbiome research, studies
  • Infection Prevention
  • Fecal Microbiota Restoration and Transplants for Adults & Pediatrics
  • A Panel Of C. diff. Infection Survivors
  • Antibiotic Stewardship
  • Healthcare EXPO
    ……………………and much more.

You won’t want to miss out on this opportunity to learn from
International topic experts delivering data directed at evidence-based
prevention, treatments, and environmental safety in the C. diff.
and healthcare community.

Gain insights on September 20th that will not be available anywhere else with an opportunity to receive up-to-date data on major topics in this program being presented in one day.

5 Leading reasons to attend this dynamic conference:

  • Learn from leading healthcare professionals, clinicians, researchers, and industry.
  • Networking opportunities with new and reconnect with those in the healthcare community with similar interests.
  • Gain breakthrough results through research in progress and gaining positive results. Programs focused on Antibiotic-resistance such as the  Antibiotic Stewardship making a difference. Front line developments in progress focused on C. diff. infection prevention, treatments, environmental safety.
  • Implement and share the knowledge well after the conference ends.  Every attendee receives a booklet with guest speakers information, media to review audio programs, and Health Expo Sponsor information focused on the important agenda topics.
  • Embrace the opportunity, with all of the topic experts presenting, and hold the conference in the highest priority from the participation in this conference to an audience of medical students, and fellow healthcare professionals, who will benefit the most from the data and gain tools to overcome the barriers facing healthcare each day.

“The information and up-to-date studies shared at the 2015 conference added to an existing knowledge base that helps us to continue delivering quality care in the medical community.”   Linda Davis, RN,BSN

 ……………………………………………………………………………………………………………..

REGISTRATION FEES:

$75.00  —  Conference Registration

$30.00  —  Student Conference Registration (Student ID To Be Presented At the Door)

TO REGISTER Click on the “Raising C. diff. Awareness” Ribbon below

CDiffAwarenessRibbon2015

Room accommodations are available —  Complete and Confirm 

by August 19th to reserve your hotel reservations.   

To create a reservation please click on the DoubleTree By Hilton Logo below – – – – – –

DoubleTreeLogo

……………………………………………………………………………………………………………………….

 A suggested travel coordinator, for your convenience

LibertyTraveldownloadMichael Beckman — Team Leader,  Liberty Travel, 467 Washington Street, Boston, MA  02111
617-936-2435
Michael.Beckman@flightcenter.com

 For Additional Information visit the C Diff Foundation Website:

https://cdifffoundation.org/

https://cdifffoundation.org/

And Click on the 2016 September Conference Tab

 

Follow us on Twitter
@cdiffFoundation
#Cdiff2016

IDSA and SHEA Release New Antibiotic Stewardship Guidelines

In The News

April 2016

Preauthorization of broad-spectrum antibiotics and prospective review after two or three days of treatment should form the cornerstone of antibiotic stewardship programs to ensure the right drug is prescribed at the right time for the right diagnosis. These are among the numerous recommendations included in new guidelines released by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) and published in the journal Clinical Infectious Diseases.

“Initially, antibiotic stewardship was more focused on cost savings, and physicians responded negatively to that, because they often felt it was best to give patients the newest, most expensive drug,” said Tamar Barlam, MD, lead co-author of the guidelines, director of the antibiotic stewardship program at Boston Medical Center and associate professor of medicine at Boston University Medical School. “While these programs do save hospitals money, their most important benefit is that they improve patient outcomes and reduce the emergence of antibiotic resistance. When we say stewardship, we really mean stewardship, and increasingly, doctors are realizing it’s important and necessary.”

The White House has called for hospitals and healthcare systems to implement antibiotic stewardship programs by 2020 to ensure appropriate use of these vital drugs and reduce resistance, an escalating problem that threatens the ability to effectively treat often life-threatening infections.

The new guidelines replace those originally created to help with the development of programs when antibiotic stewardship was in its infancy, and instead focus on specific strategies that the evidence suggests are most beneficial to ensure the program will be effective and sustainable. They also note it is key that these programs tailor interventions based on local issues, resources and expertise. To ensure that, the guidelines recommend the programs be led by physicians and pharmacists and rely on the expertise of infectious diseases specialists.

“We want hospital administrators to understand the importance of giving antibiotic stewardship their full support to ensure its success,” said Sara Cosgrove, MD, MS, lead co-author of the guidelines, president-elect of SHEA and associate professor of medicine and epidemiology at Johns Hopkins University, and director of the antimicrobial stewardship program and associate hospital epidemiologist at The Johns Hopkins Hospital, Baltimore. “Distributing a few brochures or holding grand rounds won’t do it. It’s vital that antibiotic stewardship be integrated into the hospital’s culture and that infectious disease specialists guide strategies that have been shown to work.”

The guidelines note that more research needs to be done to determine how to ensure antibiotic stewardship is most effective. However, the best evidence to date suggests a number of components, including the following, will help ensure the implementation of an effective antibiotic stewardship program.

  • Preauthorization or prospective audit and feedback – Targeted antibiotics, such as those that treat emerging drug-resistant bacterial infections, should require preauthorization. This means providers need to get approval to use antibiotics before they are prescribed. Prospective audit and feedback can be an alternate strategy or combined with preauthorization. Prospective audit allows antibiotic stewards to engage the prescribing clinician after the antibiotic has been used, typically after two or three days, to optimize antibiotic treatments. Both methods can reduce antibiotic misuse and decrease the development of resistance. Hospitals should choose one or both of these methods as part of their program based on their local resources and expertise.
  • Syndrome-specific interventions – The guidelines recommend focused multifaceted interventions for the treatment of specific syndromes, rather than trying to improve treatment of all infections at once. For example, Dr. Barlam said those leading a hospital’s antibiotic stewardship program might take a close look at management of pneumonia during winter, including making recommendations to shorten the amount of time people are treated and switching to an oral agent more quickly, and then measuring the results of those interventions. In the fall, the program might focus on urinary tract infections and then several months later, switch to skin and soft tissue infections. “This method makes stewardship more manageable and provides a targeted and clear treatment message rather than trying to disseminate 100 different lessons at the same time,” she said.
  • Rapid diagnostic testing – The guidelines note that rapid diagnostic testing of respiratory specimens can help determine if the cause is viral and therefore reduce the inappropriate use of antibiotics. They also note that the rapid testing of blood cultures in addition to conventional culture is helpful, but should be guided by the antibiotic stewardship team for maximum benefit to the patient.

Other recommendations include reducing the use of antibiotics associated with Clostridium difficile infection, implementing antibiotic time-outs and other strategies to encourage prescribers to perform routine reviews of regimens and using computerized clinical decision support if possible.

The guidelines do not recommend relying solely on passive educational materials to implement antibiotic stewardship because any improvement likely will not be sustained. Lectures and brochures should be used to supplement strategies such as antibiotic preauthorization and prospective audit and feedback, the authors note.

AT A GLANCE

  • Preauthorization and prospective review of antibiotics are among the many recommendations to ensure antibiotic stewardship programs are most effective, suggest new guidelines from IDSA/SHEA.
  • Antibiotic stewardship programs should be led by physicians and pharmacists, including ID specialists, who have the expertise and education to ensure the right drug is being prescribed at the right time for the right diagnosis.
  • Antibiotic stewardship programs must be based on the specific problems identified by the healthcare facility and a realistic examination of available resources to ensure interventions are performed with consistency.
  • These programs have been shown to improve patient outcomes, reduce antibiotic resistance and save money.

In addition to Drs. Barlam and Cosgrove, the antibiotic stewardship program guidelines panel includes: Lilian Abbo, Conan MacDougall, Audrey N. Schuetz, Ed Septimus, Arjun Srinivasan, Timothy Dellit, Yngve T. Falck-Ytter, Neil Fishman, Cindy W. Hamilton, Timothy C. Jenkins, Pamela A. Lipsett, Preeti N. Malani, Larissa S. May, Gregory J. Moran, Melinda M. Neuhauser, Jason Newland, Christopher A. Ohl, Matthew Samore, Susan Seo and Kavita K. Trivedi.

IDSA and SHEA individually have published myriad treatment guidelines and together have published several, including the prevention of healthcare-associated infections and antimicrobial prophylaxis in surgery.

As with other IDSA and SHEA guidelines, the antibiotic stewardship guidelines will be available in a smartphone format and a pocket-sized quick-reference edition.

The full guidelines are available free on the

IDSA website at http://www.idsociety.org

 

SHEA website at http://www.shea-online.org.

 

To read this article in its entirety click  on the following link:

http://www.eurekalert.org/pub_releases/2016-04/idso-nas041216.php

 

Xenex’s xenon light Germ-Zapping Robots™ Decrease Infection Rates Significantly At Orlando Florida Health South Seminole Hospital

Xenex_LogoLockups_PantoneC

Infection rates decreased significantly at Orlando Health South Seminole Hospital after the hospital began using Xenex’s xenon light Germ-Zapping Robots™ for room disinfection, according to a new peer-reviewed study published in the American Journal of Infection Control (AJIC). This is the eighth peer-reviewed study that demonstrates how a hospital successfully reduced its infection rates after utilizing Xenex Disinfection Services’ unique Xenon Full-Spectrum Disinfection™ technology to disinfect its rooms. Xenex Germ-Zapping Robots™ have been credited for helping healthcare facilities in the U.S. decrease their Methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile (C.diff) and Surgical Site infection rates by more than 50, 70 and 100 percent respectively.

Xenex’s xenon light disinfection system is the only disinfection system that uses pulsed xenon to create light that covers the entire germicidal spectrum. The Xenex system is the only ultraviolet light disinfection technology shown, in multiple peer-reviewed published studies, to help hospitals reduce infection rates.

According to the new AJIC study, South Seminole Hospital reported a 61 percent reduction in combined Vancomycin-resistant enterococci (VRE), MRSA and C.diff infection rates in its Intensive Care Unit (ICU), an 87 percent reduction in its ICU VRE infection rate, and a 29 percent reduction facility-wide in combined VRE, MRSA and C.diff infection rates after it began using Xenex’s xenon light technology. The hospital estimates that it saved $730,000 based on the number of C.diff and VRE infections that were avoided.

The study titled “Impact of pulsed xenon ultraviolet light on hospital-acquired infection (HAI) rates in a community hospital” analyzed the efficacy of pulsed xenon light in two different deployment strategies.

The difference in infection rate reduction was associated with the two different utilization strategies, which indicates best practices for pulsed xenon disinfection. ICU discharges and transfers were disinfected with Xenex Germ-Zapping Robots with a goal of all terminal cleans.

As a result, the combined VRE, MRSA and C.diff infection rates decreased 61 percent. Non-ICU discharges and transfers were disinfected with Xenex robots for C.diff cases only, resulting in a 29 percent decrease in VRE, MRSA and C.diff infection rates facility wide.

“This is an exciting study because it demonstrates best practices for pulsed xenon automated disinfection,” said Dr. Mark Stibich, Chief Scientific Officer at Xenex. “Previous studies have shown that the number of rooms disinfected with the Xenex robot correlates to the infection rate reduction the hospital will experience. This study shows that it’s more effective to use the Xenex robot to disinfect as many rooms as possible versus only disinfecting rooms where patients are known to have an infection. Our pulsed xenon robot works in a five-minute disinfection cycle, so they are able to quickly disinfect multiple rooms per day in a facility – leading to dramatic reductions in infection rates.”

Designed for speed, effectiveness and ease of use, hospital cleaning staff operate the Xenex robot without disrupting hospital operations. The robot pulses intense UV light covering the entire UV spectrum, destroying viruses, bacteria and bacterial spores in a five-minute disinfection cycle. Without contact or chemicals, the robot eliminates harmful microorganisms safely and effectively. According to Xenex customers, the robot can disinfect 30-62 hospital rooms per day, including: patient rooms, operating rooms, equipment rooms, emergency rooms, intensive care units and public areas.

Proven to Reduce HAI Rates

MD Anderson Cancer Center, the Central Texas Veterans Health Care System, Cooley Dickinson Health Care, Trinity Medical Center and other hospitals have published 14 studies providing evidence of the robot’s efficacy in highly regarded scientific journals that include the American Journal of Infection Control (AJIC), Journal of Infection Prevention, Infection Control & Hospital Epidemiology (ICHE) and BMC Infectious Diseases.

About Xenex Disinfection Services

Xenex’s patented Full Spectrum™ pulsed xenon UV room disinfection system is used for the advanced disinfection of healthcare facilities. Due to its speed and ease of use, the Xenex system has proven to integrate smoothly into hospital cleaning operations. The Xenex mission is to save lives and reduce suffering by eliminating the deadly microorganisms that cause HAIs. The company is backed by well-known investors that include Brandon Point, Battery Ventures, Targeted Technology Fund II and RK Ventures. For more information, visit www.xenex.com.

 

Resource:

http://www.businesswire.com/news/home/20160301006521/en/Infection-Rates-Decline-Florida-Hospital-Xenex-Germ-Zapping

Hospital Collaborative Measures Show Positive Results In Driving Down C difficile Infection (CDI) Rates In New York

NewspaperII

In the news

Each hospital had been trying to combat C. difficile on its own, but they were often outwitted by the hardy spore, which is fueled by overuse of antibiotics, spread by hands  and able to survive on bed rails, call buttons and doorknobs for as long as five months if not longer and cleaned off.

Plus, it was traveling: Patients in one hospital or nursing home were often discharged and then admitted to another. Dealing with the mess was costing the hospitals an estimated $4 million to $5 million a year.

So they did something rare for competing health-care systems. Four hospitals joined forces to beat back the debilitating bug, forming a C. difficile prevention collaborative. Six nursing homes that share patients with the hospitals and had a huge C. difficile problem of their own then formed a separate alliance.

It paid off: In the 12 months ended in September 2015, rates of C. difficile infections fell 36% from 2011 levels across the hospitals, which initially were in three but are now in two health-care systems: the University of Rochester Medical Center and Rochester Regional Health System.

“It’s not very simple—you have to have a multidisciplinary approach to prevent this infection,” says Ghinwa Dumyati, who leads both the hospital and nursing-home collaboratives as an infectious-disease physician with the Center for Community Health at the University of Rochester Medical Center. “We needed to work together.”

A good cleaning

Hospitals compete intensely for patients, doctors and insurance dollars, but when it comes to safety, they are increasingly collaborating to solve common problems, according to Arjun Srinivasan, an expert at the Centers for Disease Control and Prevention in the prevention of health-care-associated infections. The CDC says working together allows hospitals to more effectively fight infections caused by drug-resistant bacteria and C. difficile because the bugs are intractable and the difficulties each facility faces are similar. Plus, Dr. Srinivasan says, “hospitals share those patients.”

New federal requirements to improve health-care quality, such as public reporting of health-care-associated infections and penalties for readmissions, also are prodding hospitals to collaborate more on safety issues, Dr. Srinivasan and hospital executives say.

C. difficile is the most common pathogen causing health-care-associated infections in U.S. hospitals, according to the CDC. It led to approximately 453,000 infections and 29,000 deaths in the U.S. in 2011, according to a study last year in the New England Journal of Medicine.

Infections occur when someone ingests C. difficile and takes antibiotics that wipe out the good bacteria in their gut. That leaves the C. difficile to flourish in the colon, producing diarrhea that can last for weeks or months. The elderly are particularly at risk of infection because their immune systems may be weak, and they are frequent users of hospitals and nursing homes.

Rochester’s C. difficile-prevention collaborative began in 2011, funded by the health-care

systems involved and a large regional insurer, Excellus BlueCross BlueShield. It grew out of an earlier initiative that Dr. Dumyati had led that sharply reduced bloodstream infections from central lines, or catheters, inserted in the body. This time, the collaborative—Dr. Dumyati, along with doctors, infection preventionists and others from the hospitals—

chose to target C. difficile. “We knew we had a lot of cases,” she says.

First, the collaborative focused on cleaning procedures. The hospitals taught staff to scrub long and hard with bleach wipes to get rid of super-resilient C. difficile in hospital rooms. “Just like if you’re washing a plate, you have to apply pressure to get food off,” says Jeanna Hibbert, who cleans rooms at Strong Memorial Hospital, one of the four participating hospitals.

They also introduced inspections of cleaned rooms, using a tool that checks for even small amounts of contamination. “That was new and extraordinarily helpful,” says Robert Panzer, chief quality officer and associate vice president at Strong Memorial.

Each hospital made changes in its own way, and borrowed ideas from the others. Strong Memorial dedicated a crew to clean the rooms of discharged C. difficile patients after determining that it takes an hour and half—twice as long as normal—to properly clean them, adopting a practice from its sister, Highland Hospital.

After the collaborative laid out a policy for treating less severe forms of pneumonia, Strong Memorial pharmacists changed an electronic order form for antibiotics to prevent physicians treating those infections from prescribing a class of drugs linked to C. difficile infection without special approval, says Dr. Dumyati.

Across town at Rochester General Hospital, staff promoted the new pneumonia policy in a newsletter for doctors. Use of the desired antibiotic, doxycycline, for pneumonia more than tripled in a year; use of the one it replaced fell 48%, the hospital says.

The team at Rochester General also created a poster with new guidelines for diagnosing and treating urinary-tract infections after the collaborative determined that five out of six of its hospital patients treated for them don’t actually have them. Dr. Dumyati adopted it for use in the nursing homes she had started to work with, with a grant from the state.

The new policies have helped Rochester General strengthen an antibiotic stewardship program it adopted a few years ago, in which a team of experts reviews antibiotic prescriptions, says Maryrose Laguio-Vila, the program’s director. “We gain insight into whether what we’re doing is along the right track or can be tweaked in a certain way.”

The collaborative has helped all of the hospitals improve their practices and patient care, says Nayef El-Daher, chief of infectious disease at Unity Hospital. “When we started the project, every one of us had [our] own ideas and protocols,” he says.

The next front

Dr. Dumyati feeds data on C. difficile infection rates and other measures every quarter to each of the hospitals, so that they can see how they’re doing. “The data really drive where we go next,” she says.

Next, she hopes to take the new policies to doctors’ and dentists’ offices. About 35% of all C. difficile infections aren’t linked to stays in hospitals or long-term-care facilities, according to the NEJM study.

“It’s fairly clear that you have to work with the nursing homes and you have to work across the community to make progress,” says Mark Shelly, chief of infectious disease at Highland Hospital. “Otherwise we’ll be pointing across the fence for a long time.”

 

To read the article in its entirety click on the link below:

 

http://www.wsj.com/articles/rochester-hospitals-unite-to-defeat-a-common-foe-c-difficile-1455592271

C Diff Foundation Welcomes Dr. Barbara McGovern, MD

BarbaraMcGovern (2)

We are pleased to welcome Dr. Barbara McGovern,MD to the C Diff Foundation.  Dr. McGovern  presides as a member of the Foundation’s Medical Advisory Board.

Dr. Barbara McGovern is Vice President of Medical Affairs at Seres Therapeutics. She obtained her M.D. degree from the Albert Einstein College of Medicine and did her residency and infectious disease training at Tufts Medical Center where she worked many years as an infectious disease specialist.

 

 

Her clinical career began in working with HIV-infected patients, including taking care of incarcerated women with HIV and hepatitis C co-infection. When the rates of morbidity and mortality from HIV declined on potent ant-iretroviral therapy, she was one of the first to observe that end-stage liver disease secondary to hepatitis C infection had become a leading cause of death in HIV-infected patients and subsequently devoted her clinical research career to the management of these patients.

Dr. McGovern served as a member of the Antiviral Advisory Committee for the U.S. Food and Drug Administration (FDA) and also served several years on the Department of Health and Human Services Guideline Committee for management of viral hepatitis in HIV-infected patients. Dr. McGovern was also an Associate Editor at Clinical Infectious Diseases and was a Deputy Editor at Up-To-Date, an international medical journal where she founded a Global Health section for the care of patients living in developing countries.

Over the past three years she started working within the pharmaceutical arena and is currently head of Medical Affairs at Seres Therapeutics, which is developing microbiome-based therapies. Their lead microbiome therapeutic drug is SER-109, which is being evaluated in a Phase 2 clinical trial for recurrent Clostridium difficile infection.